By Steven Melendez ( May 9, 2012, 5:12 PM EDT) -- Despite safety concerns, a U.S. Food and Drug Administration advisory panel voted 8-2 Wednesday to recommend approval of Pfizer Inc.'s new rheumatoid arthritis drug for patients who don't adequately respond to other treatments....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.